Kewaunee Scientific Corporation files regulatory reports that document operating results, governance actions and material corporate disclosures for its laboratory furniture and biosafety products business. Recent Form 8-K reports cover earnings releases, fiscal-quarter financial condition disclosures, non-GAAP reconciliations, earnings announcement notices, and Regulation FD investor presentation materials.
The company's filings also disclose shareholder voting results, director appointments, auditor ratification, advisory compensation votes, and the registered common stock traded under KEQU on The Nasdaq Global Market. Business descriptions in the filings identify Kewaunee's laboratory casework, fume hoods, modular systems, workstations, benches, biological safety cabinets, epoxy resin surfaces and sinks, and Nu Aire laboratory products.
Campbell John Jette reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific director John Jette Campbell received an equity grant of 2,013 shares of Common Stock as part of his annual compensation. The shares were awarded at no cash cost under the company’s 2023 Omnibus Incentive Plan, increasing his directly held position to 2,703 shares after the award.
GEHL KEITH M reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific director Keith M. Gehl received a grant of 2,013 shares of Common Stock on May 1, 2026. The shares were awarded under the company’s 2023 Omnibus Incentive Plan as the equity portion of his annual compensation and were granted at $0.00 per share. Following this award, he directly holds 22,409 shares of Kewaunee Scientific common stock.
Kewaunee Scientific director Margaret B. Pyle reported a bona fide gift of 2,750 shares of common stock held indirectly through a trust. The shares were transferred on March 26, 2026, as a gift to five grandchildren, with no sale proceeds involved. After the transfer, trust-related indirect holdings reported for her total 36,891 shares, and a separate 5,000 shares are reported as held indirectly by her spouse.
Kewaunee Scientific Corporation reported quarterly net sales of $69,399,000, slightly above $67,167,000 a year ago, and nine‑month net sales of $210,599,000 versus $163,324,000, reflecting growth helped by the Nu Aire acquisition. Nine‑month gross profit was $59,195,000, with gross margin improving to 28.1% of sales from 27.4%.
Net earnings attributable to Kewaunee Scientific Corporation for the nine months were $6,230,000, down from $6,555,000, with diluted earnings per share of $2.09 compared to $2.20. Order backlog was $183.2 million at January 31, 2026, below $221.6 million a year earlier and $214.6 million at April 30, 2025.
Operating activities generated $13,173,000 of cash, up from $5,376,000, while cash, cash equivalents and restricted cash decreased to $10,347,000 from $17,164,000. The company refinanced its Nu Aire seller notes, repaying $23,000,000 of principal and related interest, and ended the period with total long‑term debt of $21,333,000 versus $37,685,000, remaining in compliance with loan covenants.
Kewaunee Scientific Corporation reported mixed results for its third quarter ended January 31, 2026. Sales were $69.4 million, up 3.3% from $67.2 million a year earlier, and consolidated EBITDA was $3.8 million, slightly above $3.7 million.
Despite higher sales, net earnings attributable to Kewaunee fell to $0.7 million, down from $1.4 million, with diluted EPS declining to $0.23 from $0.45. Domestic sales decreased 2.0%, while international sales grew 21.4%, lifting international segment EBITDA to $2.0 million from $0.8 million.
The order backlog was $183.2 million versus $221.6 million a year earlier, reflecting softer construction-related activity. The company reduced long-term debt from $60.7 million on April 30, 2025, to $42.3 million, improving its debt-to-equity ratio to 0.68-to-1 from 0.99-to-1 as it continues integrating the Nu Aire acquisition and investing in its corporate platform.
Kewaunee Scientific Corporation announced that it plans to release its third quarter fiscal year 2026 financial results on March 11, 2026, after the close of trading. The results will be posted on the company’s website.
The company describes itself as a global provider of laboratory, healthcare, and technical furniture and related equipment, and notes that its portfolio now includes products from its newly acquired subsidiary, Nu Aire.
Northern Trust Corporation reported beneficial ownership of 252,328 shares of Kewaunee Scientific common stock, representing 8.8% of the outstanding class as of 12/31/2025. Northern Trust has sole voting and dispositive power over 15,967 shares and shared power over 236,361 shares.
The shares were acquired and are held in the ordinary course of business, and Northern Trust certifies they are not held for the purpose or effect of changing or influencing control of Kewaunee Scientific.
Kewaunee Scientific Corporation’s President and CEO, Thomas David Hull III, who is also a director, reported a sale of company stock. On 01/07/2026, he sold 2,177 shares of Common Stock, reported at a weighted average price of $37.5 per share. The shares were sold in multiple trades at prices ranging from $37.21 to $37.54. After this transaction, he beneficially owns 33,000 shares of Kewaunee Scientific common stock directly.
Kewaunee Scientific Corporation Chief Financial Officer Donald T. Gardner III reported an open-market sale of 2,000 shares of common stock on January 6, 2026. The shares were sold at a weighted average price of $37.57, with individual trade prices ranging from $37.50 to $38.00.
Following this transaction, Gardner beneficially owned 9,564 shares of Kewaunee Scientific common stock in direct ownership. He has undertaken to provide, upon request, detailed information about the number of shares sold at each separate price within the reported range.
Kewaunee Scientific insider activity shows its President and CEO, who also serves as a director, reported a stock sale. On 12/17/2025, the reporting person sold 1,000 shares of Kewaunee Scientific common stock at a price of $39 per share. After this transaction, the insider beneficially owns 37,719 shares directly.